Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 104 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Early Psychosis Clear all
Withdrawn Not applicable Interventional

Repetitive Transcranial Magnetic Stimulation (rTMS) Self-Referential Processing (rTMS-SRP)

NCT04068857
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
rTMS
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 23, 2026, 1:00 PM EDT
Completed Phase 4 Interventional Results available

Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics

NCT02360319
View directory record Official record
Conditions
Schizophrenia
Interventions
Any FDA approved antipsychotic agent, aripiprazole long acting injectable formulation
Drug
Lead sponsor
Vanguard Research Group
Other
Eligibility
18 Years to 35 Years
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
39
States / cities
Tucson, Arizona • Granada Hills, California • Palo Alto, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 23, 2026, 1:00 PM EDT
Not listed No phase listed Observational

Early-Phase Schizophrenia: Practice-based Research to Improve Outcomes

NCT04004364
View directory record Official record
Conditions
First Episode Psychosis
Interventions
Coordinated Specialty Care (CSC)
Other
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
700 participants
Timeline
2020 – 2025
U.S. locations
1
States / cities
Lauderdale Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 23, 2026, 1:00 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Remote State Representation in Early Psychosis

NCT05538832
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Schizophreniform Disorders, Psychotic Disorders, Psychotic Mood Disorders, Psychoses, Affective, Psychosis Nos/Other, Schizophrenia Spectrum and Other Psychotic Disorders
Interventions
BrainHQ Computerized Cognitive Training - Visual Perception Training Paradigm, BrainHQ Computerized Cognitive Training - Visual Cognitive Control Training Paradigm
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 30 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 23, 2026, 1:00 PM EDT
Completed Phase 2 Interventional Results available

A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia

NCT02008773
View directory record Official record
Conditions
Schizophrenia
Interventions
Valacyclovir HCI 500 mg tablets, placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
13
States / cities
Bellflower, California • Los Angeles, California • Riverside, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 23, 2026, 1:00 PM EDT
Terminated Phase 4 Interventional Results available

C-Cog in Early Course Schizophrenia Study

NCT05662306
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole Lauroxil, Computerized cognitive and functional skills training
Drug · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 23, 2026, 1:00 PM EDT
Completed No phase listed Observational

Reducing the Duration of Untreated Psychosis in the United States

NCT03369730
View directory record Official record
Conditions
First Episode Psychosis (FEP), At Risk Mental State (ARMS)
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
12 Years to 30 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 23, 2026, 1:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia

NCT01339858
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorder NOS, Schizoaffective Disorder, Schizophreniform
Interventions
N-Acetyl Cysteine, sugar pill
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
16 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 23, 2026, 1:00 PM EDT
Enrolling by invitation Not applicable Interventional

California Collaborative Network to Promote Data Driven Care and Improve Outcomes in Early Psychosis

NCT04007510
View directory record Official record
Conditions
First Episode Psychosis (FEP)
Interventions
EPI-CAL data network, Community DUP Assessment Tool
Combination Product · Diagnostic Test
Lead sponsor
University of California, Davis
Other
Eligibility
8 Years to 40 Years
Enrollment
1,329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 23, 2026, 1:00 PM EDT
Recruiting Phase 4 Interventional

Biomarkers to Enhance Early Schizophrenia Treatment

NCT06969755
View directory record Official record
Conditions
Schizophenia Disorder
Interventions
aripiprazole, risperidone, clozapine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 35 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
4
States / cities
Birmingham, Alabama • La Jolla, California • Belmont, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 23, 2026, 1:00 PM EDT
Completed Not applicable Interventional Results available

Minnesota Community-Based Cognitive Training in Early Psychosis

NCT03079024
View directory record Official record
Conditions
Schizophrenia, Psychosis, Schizoaffective Disorder, Schizophreniform Disorders, Psychosis NOS, Depression Psychotic Feature, Bipolar Disorder With Psychotic Features, Unspecified Psychosis
Interventions
Targeted Cognitive Training, General Cognitive Exercises, Coordinated Specialty Care for First Episode Psychosis
Device · Other
Lead sponsor
University of Minnesota
Other
Eligibility
16 Years to 35 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 23, 2026, 1:00 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

State Representation in Early Psychosis 2

NCT07834203
View directory record Official record
Conditions
Early Psychosis, Psychosis, Schizophrenia, Bipolar Disorder With Psychosis, Schizoaffective Disorder
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 45 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 23, 2026, 1:00 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia

NCT03230864
View directory record Official record
Conditions
Treatment-resistant Schizophrenia
Interventions
Lu AF35700, Risperidone, Olanzapine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
10
States / cities
San Diego, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 23, 2026, 1:00 PM EDT
Completed Phase 2 Interventional Results available

N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis

NCT01354132
View directory record Official record
Conditions
Schizophrenic Psychoses
Interventions
n-acetylcysteine, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Oct 23, 2026, 1:00 PM EDT
Completed Not applicable Interventional

Integrated Metacognitive Therapy in First Episode Psychosis

NCT02131116
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
Interventions
Integrated Metacognitive Therapy, Treatment as Usual
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 23, 2026, 1:00 PM EDT
Withdrawn Not applicable Interventional

HOPE TEAM - Clinical High Risk Group CBSST

NCT03738046
View directory record Official record
Conditions
Prodromal Symptoms, Prodromal Stage, Prodromal States, Psychosis
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
13 Years to 19 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 23, 2026, 1:00 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Levetiracetam in Early Psychosis

NCT03129360
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizo Affective Disorder, Schizophreniform
Interventions
Levetiracetam, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 35 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Oct 23, 2026, 1:00 PM EDT
Completed Not applicable Interventional

Transcranial Direct Current Stimulation and Effects on Early Auditory Processing in Schizophrenia

NCT03537703
View directory record Official record
Conditions
Schizophrenia
Interventions
Active tDCS + Auditory Training, Active tDCS + Control Condition, Sham tDCS + Auditory Training
Combination Product
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 23, 2026, 1:00 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder

NCT03187769
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorders, Bipolar I Disorder
Interventions
ALKS 3831, Olanzapine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
16 Years to 40 Years
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
25
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Garden Grove, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 23, 2026, 1:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia

NCT03323437
View directory record Official record
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders
Interventions
Risperidone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 35 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Oct 23, 2026, 1:00 PM EDT
Completed Not applicable Interventional

Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis

NCT02566057
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders, Bipolar Disorder
Interventions
PGx testing guided treatment (PGT)
Biological
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 64 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 23, 2026, 1:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

State Representation in Early Psychosis - Project 4

NCT05664594
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizoaffective Disorder
Interventions
Computerized Cognitive Training
Device
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 23, 2026, 1:00 PM EDT
Recruiting Phase 1 Interventional

A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia

NCT07734493
View directory record Official record
Conditions
Schizophrenia
Interventions
LTX-001 once daily, Placebo, LTX-001 twice daily
Drug
Lead sponsor
Leal Therapeutics, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Little Rock, Arkansas • Los Alamitos, California • DeLand, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 23, 2026, 1:00 PM EDT
Active, not recruiting Not applicable Interventional

EPI-MINN: Targeting Cognition and Motivation

NCT05112432
View directory record Official record
Conditions
Psychosis
Interventions
Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
Device · Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 40 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Duluth, Minnesota • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 23, 2026, 1:00 PM EDT